CHA Vaccine Research Institute Past Earnings Performance
Past criteria checks 0/6
CHA Vaccine Research Institute has been growing earnings at an average annual rate of 9.1%, while the Biotechs industry saw earnings growing at 14.4% annually. Revenues have been declining at an average rate of 5.1% per year.
Key information
9.1%
Earnings growth rate
30.8%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | -5.1% |
| Return on equity | -4.3% |
| Net Margin | -271.1% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How CHA Vaccine Research Institute makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 543 | -1,472 | 2,136 | 4,174 |
| 31 Dec 23 | 294 | -1,749 | 2,197 | 3,949 |
| 30 Sep 23 | 294 | -5,029 | 2,327 | 4,425 |
| 30 Jun 23 | 294 | -4,602 | 2,477 | 3,798 |
| 31 Mar 23 | 184 | -6,826 | 2,409 | 4,086 |
| 31 Dec 22 | 179 | -6,715 | 2,357 | 3,855 |
| 30 Sep 22 | 179 | -18,877 | 3,513 | 3,406 |
| 30 Jun 22 | 179 | -18,806 | 3,357 | 3,316 |
| 31 Mar 22 | 617 | -18,410 | 3,215 | 3,340 |
| 31 Dec 21 | 500 | -18,420 | 3,199 | 3,140 |
| 30 Sep 21 | 523 | -7,014 | 1,731 | 3,039 |
| 30 Jun 21 | 547 | -7,731 | 1,648 | 3,238 |
| 31 Mar 21 | 62 | -7,005 | 1,404 | 3,011 |
| 31 Dec 20 | 78 | -6,240 | 1,038 | 3,124 |
| 31 Dec 19 | 126 | -2,980 | 469 | 2,458 |
| 31 Dec 16 | 173 | -1,404 | 269 | 255 |
Quality Earnings: A261780 is currently unprofitable.
Growing Profit Margin: A261780 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A261780 is unprofitable, but has reduced losses over the past 5 years at a rate of 9.1% per year.
Accelerating Growth: Unable to compare A261780's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A261780 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (13.4%).
Return on Equity
High ROE: A261780 has a negative Return on Equity (-4.33%), as it is currently unprofitable.